Cormedix Inc (STU:19KA)
€ 9.65 0.25 (2.66%) Market Cap: 601.04 Mil Enterprise Value: 558.66 Mil PE Ratio: 0 PB Ratio: 10.17 GF Score: 52/100

CorMedix Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 03:30PM GMT
Release Date Price: €4.52 (-0.88%)
Jason Butler
JMP Securities LLC - Analyst

Thanks again. Good morning, everybody. I appreciate you being with us this morning at the JMP Securities Life Science Conference. Excited to have CorMedix join us next. And with us is CEO, Joe Todisco. Joe, thank you for being with us. Super exciting day with the announcement of the DefenCath NDA submission. So I'm sure we will get to that in a minute.

Questions & Answers

Jason Butler
JMP Securities LLC - Analyst

But before we do that, I just wanted to start off. You've been CEO now for a little over a year. Can you just give us a quick overview of the company, DefenCath, and to what originally drew you to the opportunity?

Joe Todisco
CorMedix Inc. - CEO

Sure. Look, I think I'm a year and three days to be exact. CorMedix is essentially a pre-commercial stage biotech. Our lead product, DefenCath is a catheter lock solution, with the initial indication focused on preventing catheter-related bloodstream infections in hemodialysis patients that have a central venous

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot